Study Design
This protocol follows the Consolidated Standards of Reporting Trials (CONSORT) Statement on randomized trials of non-pharmacological treatment. The study will be reported according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement (Additional file 1). The Clinical Trials Ethics Committee of Huazhong University of Science and Technology provided ethical approval on 24 October 2018. The trial was registered in the Chinese Clinical Trial Registry, ChiCTR1900026656, on 17 October 2019.
The AOT-EXO trial is a multicentre, prospective, three-group randomized controlled trial (RCT). It will be implemented in the Department of Rehabilitation Medicine of Tongji Hospital, Optical Valley Branch of Tongji Hospital and Hubei Province Hospital of Integrated Chinese & Western Medicine in Wuhan, China. A flowchart overview of the study is presented in Figure 1. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) for enrolment, interventions and assessments is presented in Figure 2.
Prior to study participation, written informed consent (Additional file 2) will be obtained from eligible patients in accordance with the most recent Declaration of Helsinki. In total, 132 eligible subjects will be randomly allocated into three groups equally: (1) CT group (conventional therapy); (2) EXO group (exoskeleton therapy); and (3) AOT-EXO group (action observation treatment-based exoskeleton therapy). All subjects will receive assessments at baseline, post-intervention (after 4 weeks) and follow-up (after 12 weeks). To avoid assessment bias, an independent evaluator at each centre blinded to the randomization procedure and group allocation will complete all outcomemeasures.
Participants
The inclusion criteria are as follows: (1) age 18-80; (2) clinical diagnosis of stroke (cerebral infarction, primary intracerebral haemorrhage, subarachnoid haemorrhage) within 6 months before enrolment; (3) Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score 8-47; (4) Mini-Mental State Examination (MMSE) score ≥22 and compliance with the interventions; and (5) provision of written informed consent [20, 21].
The exclusion criteria are as follows: (1) more than one stroke (patients with previous transient ischaemic attack could participate); (2) other current significant impairment of the upper limb, e.g., fixed contracture, shoulder subluxation, or recent fracture; (3) severe visual deficits or unilateral spatial neglect; (4) diagnosis likely to interfere with rehabilitation or outcome assessments, e.g., traumatic brain injury, meningitis, epilepsy; and (5) current participation in another upper limb rehabilitation trial [21, 22]. Of note, patients with contraindications to transcranial magnetic stimulation and functional magnetic resonance imaging (e.g., pacemakers, claustrophobia, implanted metal, implantable electronic devices, etc.) will NOT be excluded but will NOT receive corticospinal excitability or fMRI examination.
Randomization and Blinding
The following information will be collected: demographic information, medical history, medication and rehabilitation details, stroke type, time post stroke onset, complications, comorbidity, and baseline outcome measures.
We will randomize all the included patients into the three groups at a ratio of 1:1:1 through a computer-generated random number table centrally generated in Tongji Hospital. An independent statistician will prepare the sequentially numbered, opaque, sealed envelopes before the start of enrolment. No randomization number will be reutilized in any case. Because the training methods differ between groups and according to the features of the robot, it is not feasible to blind the subjects, therapists or physicians participating in the trial. Therefore, an independent evaluator at each centre blinded to the randomization procedure and group allocation will assess all outcome measures (baseline, post-intervention and follow-up measures).
Intervention
Stroke patients in all groups will require multidisciplinary medication and rehabilitation; hence, their routine treatment programmes will continue as usual with the additional four-week intervention. The intervention will be delivered at the same frequency and duration in the three groups: 45 minutes daily, 5 days/week for 4 weeks. The same therapists and therapy assistants will deliver all the intervention sessions at each centre [12].
Participants in the CT group (conventional therapy) will receive the therapist-mediated arm intervention using conventional therapy techniques, such as muscle strengthening, stretching, arm exercises or gross-motor training, fine-motor training and functional task practice. This therapy matches that in the other groups with respect to schedule and the form and intensity of movements. The programmes in the conventional group will progress to meet the patient’s training goals.
The EXO group (exoskeleton therapy) will receive intensive task-specific training in the three-dimensional workspace of the human arm involving shoulder (flexion/extension, horizontal abduction/adduction, external/internal rotation) and elbow (flexion/extension, pronation/supination) movements (Armule ®, Intelbot Intelligent Machine Co., Ltd, Wuhan, China). Each training session consists of exercises in the following order: 5-minute passive mode plus 15-minute assist-as-needed mode for twice with a 5-minute break between intervals. In the passive mode, the exoskeleton manipulates the upper limb in a three-dimensional trajectory predetermined by the therapists according to the patient’s goals. In the assist-as-needed mode, the patients practice games and ADL training programmes dedicated to shoulder and elbow movements. When the patient is unable to complete the tasks actively, assistive force will supply the upper extremity with passive movement to the target positions.
The AOT-EXO group (action observation treatment-based exoskeleton therapy) will share a training routine with the EXO group. The difference is as follows: during the assist-as-needed session in the AOT-EXO group, patients will be instructed to carefully watch video clips showing upper limb movements and related daily routine tasks before training. Each session will last approximately 15 minutes (2-minute action observation and 3-minute action execution for three movement sequences) twice per day (upper limb movements followed by related daily routine tasks in the second session). The actors in the videos will be healthy volunteers. The video clips will be obtained with a Canon camera in the first-person perspective [23]. Patients will be presented with three movement sequences per week for 4 weeks with increasing difficulty (12 sequences in total).
Outcomes
All outcomes will be measured at baseline, post-intervention (at 4 weeks) and follow-up (at 12 weeks) with no charge. The primary outcome will be mean change in the Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score. This assessment examines arm movement, coordination, and reflexes, and the results are represented as a 3-point ordinal scale score with a maximum of 66 points. The FMA-UE is a reliable and valid scale with which to measure upper limb motor impairment after stroke, with higher scores indicating better motor function [24].
Secondary outcomes will be the mean change in Action Research Arm Test (ARAT) score, modified Barthel Index (MBI), kinematic metrics, resting motor threshold (rMT) and motor evoked potentials (MEP), functional magnetic resonance imaging (fMRI) and safety outcomes.
The Action Research Arm Test (ARAT) evaluates 19 tests of arm motor function, including four subscales: grasp, grip, pinch, and gross movement. Each test is given an ordinal score of 0, 1, 2, or 3, with the total score ranging from 0 to 57, with higher values indicating better arm motor status and dexterity [25].
The modified Barthel Index (MBI) is an assessment tool formulated to examine the level of independence in the basic ADL and comprises 10 categories: feeding, personal hygiene, toilet use, bladder control, bowel control, bathing, dressing, chair/bed transfer, ambulation, and stair climbing [26].
We will use kinematic metrics (Inertial Measurement Unit, IMU, Noraxon USA Inc.) to evaluate the movement smoothness (peak speed, time to peak speed, number of movement units and path ratio) and performance (pointing time and pointing accuracy) during the finger-to-nose test. The instrumented kinematic assessment can provide good sensitivity for detecting motor performance that is not captured by the clinical scales [27, 28].
Corticospinal excitability will be measured using resting motor threshold (rMT) and motor evoked potentials (MEP) from the abductor pollicis brevis(APB) muscles [29]. Patients will be instructed to sit in a comfortable chair with their hands resting on their lap during the evaluations. Transcranial magnetic stimulation (TMS MagVenture® MagPro R30 Denmark) will be performed using a figure-eight coil placed tangentially in a posterior–anterior plane at a 45° angle from the midline over the hotspot. The rMT is defined for each hemisphere as the minimal stimulator output intensity that elicits MEPs with peak-to-peak amplitudes of at least 50 µV from the contralateral APB muscle in at least five of ten trials. MEPs will be sampled during TMS at 110% rMT and will be kept constant during the following evaluations. The MEP will be recorded as zero if not evocable [30, 31].
Functional magnetic resonance imaging (fMRI) acquisition and pre-processing will be conducted as follows. Scanning will be on the same 3.0 Tesla MR scanner (Discovery LS MR 750; GE Healthcare, Chicago, IL, USA), including acquisition of high-resolution anatomical images, followed by two fMRI series of two hemiplegic-sided motor tasks: finger-to-nose motion (task 1) and finger-to-nose motion sequence observation and execution (task 2). The range of motion for each task is not controlled but rather self-determined. Each series contains 30-second epochs that alternate rest with 0.03-Hz movement. We will acquire functional images using the T2*-weighted gradient echo planer imaging sequence, which measures the blood oxygen level dependence (BOLD) signal. Scanning parameters will include 43 axial 3-mm-thick slices of the whole brain per repetition, 204 volumes/series, TR=3000 ms and TE=30 ms, matrix size=72×72, and FOV=216×216 mm2. During the fMRI scan, subjects will view a guidance video displayed on the screen. The video will run continuously with a 0.03-Hz movement cycle that is green during rest epochs, yellow during task 1 epochs and red during task 2 epochs. For all conditions, each series will consist of 5 cycles alternating between a 30-s baseline block (fixation cross) followed by a 30-s task block; yielding a total duration of each fMRI run of 10 minutes. Before entering the scanner, subjects will practice the paradigm and an investigator will observe subject movements during scanning to verify task compliance [32].
Pre-processing of fMRI data will be performed with SPM8 (The Wellcome Department of Imaging Neuroscience, University College, London, UK) running in MATLAB (version 7.9.0.529, R2016b) (The MathWorks, Natick, Massachusetts, USA). For each subject, after motion correction, the anatomical MRI will be co-registered to the mean functional image. The fMRI data pre-processing steps include (1) inter-slice timing correction to the middle slice of a volume for signal coherence; (2) realignment of the motion artefact to the first volume in the entire scanning period; (3) co-registration normalization of spatial transformation to the standardized head domain merged from all subjects’ imaging results (the Montreal Neurological Institute template, called the MNI template); and (4) spatial smoothing with a Gaussian kernel of 4 mm full to half-maximum to elevate the signal-to-noise ratio of functional responses.
Safety outcomes will include the occurrence of all adverse events and serious adverse events in accordance with the guidance of the Clinical Trials Ethics Committee of Huazhong University of Science and Technology. Possible adverse events attributable to the intervention may include shoulder pain, skin abrasion, and delayed muscle soreness, which will be observed in detail and documented. Establishing causality between the protocol and adverse events will require judgement. We will rate the relevance degree of all adverse events and the intervention in the AOT-EXO trial with an ordinal score from one to five, with higher values indicating a greater degree of relevance. Although robotic training has been proven safe in the previous studies, serious adverse events may occur related or unrelated to our protocol. We have rehearsed an in-hospital first-aid plan that can be carried out expertly under emergency circumstances and will immediately report to the project investigator together with Ethics Committee, who will determine whether the participant needs to be removed from the study and whether the trial should be adjusted or terminated.
Sample Size
The sample size was calculated by considering the primary outcome measure as the reference: a mean difference of 5 points in the FMA-UE between the AOT-EXO group and CT group, and 3 points between the AOT-EXO group and EXO group with a standard deviation of 5.0 [33]. Based on multiple comparisons significance level of 1.67% and a power of 0.8, a sample size of 40 per group will be needed. Assuming that 10% patients loss to follow-up, we will choose a sample size of 44 participants for each group and 132 participants in total. The sample size calculation was performed with PASS 2008 software.
Data Monitoring and Management
The data monitoring committee (DMC), independent from the sponsor and competing interests, will be responsible for data monitoring procedure to ensure the accuracy and completeness of the data reported by researchers. The DMC will conduct the procedure at each centre in cooperation with all investigations from institutional review board or regulatory authority. Each centre will be responsible for quality control of the informed consent, participant recruitment, intervention programme implementation and data management.
The directors of each centre will be responsible for retaining all records with complete confidentiality for 10 years after the completion or termination of the study. Each centre will apply data cleansing, identification and coding and will create an electronic data set for statistical analysis and transfer of quality control records. In cases where inconsistencies, missing values, or other problems are detected in the data set, the directors at each centre will be queried and will recheck the electronic case report form (CRF) if necessary. The principal investigator and all directors of each centre will receive full anonymous copies of the electronic data set to promote dissemination of the study results.
The sponsor will appoint the Trial Steering Committee (TSC) comprising investigators and clinical experts independent of the clinical trial. TSC will be responsible for the scientific integrity of the clinical trial, including the scientific validity of the study protocol, assessment of study quality and conduct, and scientific quality of the final study report.
Statistical Analyses
All statistical analyses will be performed using SPSS software (version 21.0, IBM Corporation, Chicago, IL). To assess the normal distribution of quantitative data, the Shapiro-Wilk test will be employed (P > 0.05). Continuous variables will be presented as the mean (SD) for normal distributions and median for non-normal distributions and categorical variables will be presented as frequencies or percentages. Baseline data between groups will be compared using Student’s t-test for continuous variables and the chi-square or Fisher’s exact tests for categorical variables. A P value < 0.05 will be considered indicative of statistical significance. All analyses will be carried out based on the intention-to-treat principle, with missing data calculated using multiple imputation. Within-group differences will be assessed using paired t tests for the normally distributed data and Wilcoxon-signed rank test for the non-parametric equivalent test. When comparing the two patient subgroups at each time point, Student’s t-test (for continuous data) and Fisher’s exact test (for categorical data) will be implemented. When examining the effect of the randomization procedure over time, two-way repeated measures analysis of variance (ANOVA) will be conducted to examine the time-treatment group interaction, with time as the within-group variable and treatment group as the between-group variable.